Aarey Drugs & Pharmaceuticals has notified stock exchanges that it sent letters to shareholders without registered email addresses, providing a web link to access the Integrated Annual Report for FY26. The disclosure was made on September 11, 2026.

The company informed the Bombay Stock Exchange and the National Stock Exchange regarding the issuance of these letters pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action ensures that members who have not registered their email addresses with the company or depository participants can still access the financial documents.

Annual Report Access Details

The letters were sent to shareholders as on the cut-off date of September 4, 2026. The Integrated Annual Report for the financial year ended March 31, 2026, is available on the company's website. Shareholders can access the document via the investors section of the official site.

Nimit Ghatalia, Director of the company, issued the notification to the exchanges. Mr. Kailash Chand Jethlia, Company Secretary and Compliance Officer, signed the letter to shareholders. The company encourages investors to update their email addresses through depository participants or the registrar to facilitate future communications and support green initiatives.

AGM and Book Closure Reminder

The company previously scheduled its 36th Annual General Meeting for Wednesday, September 30, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means. The book closure period runs from September 24, 2026, to September 30, 2026. Shareholders holding shares as of the record date will be eligible to attend the meeting and vote on resolutions.

The primary business includes adopting the audited financial statements for the year ended March 31, 2026. Shareholders will also vote on the reappointment of Mrs. Bina Ghatalia as a director and approve related party transactions. E-voting is open between September 27, 2026, at 9:00 am and September 29, 2026, at 5:00 pm.

Aarey Drugs & Pharmaceuticals Limited reported a sharp expansion in top-line growth for the quarter ended June 30, 2026, with revenue rising 145% year-on-year. However, this volume surge was not matched by profitability, as net profit before tax contracted significantly.

**Aarey Drugs & Pharmaceuticals Limited** posted total income from operations of ₹4,643.05 lakh for Q1FY26, compared to ₹1,894.29 lakh in the corresponding quarter of FY25. Despite the robust revenue performance, the company’s net profit before tax, exceptional and extraordinary items fell 59.7% to ₹51.56 lakh, down from ₹128.01 lakh in Q1FY25.

Financial Performance Overview

The company’s full-year audited results for FY26 showed total income of ₹10,736.08 lakh and a net profit before tax of ₹137.72 lakh. For the current quarter, earnings per share (basic and diluted) stood at ₹0.36 each, marginally higher than the ₹0.35 recorded in Q1FY25.

What the Numbers Show

The divergence between revenue growth and profit contraction indicates significant margin compression during the quarter. While sales more than doubled, the absolute profit contribution dropped by nearly 60%. This suggests that cost structures or input prices may have risen disproportionately to the revenue gains, eroding operational efficiency despite the strong topline momentum.

Corporate Governance

The Board of Directors approved the unaudited standalone financial results at its meeting held on August 14, 2026. The results were reviewed by the Audit Committee in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial statements are available on the company’s website and stock exchange portals.